Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 2/2013

01.06.2013 | special report

Single-agent bevacizumab as maintenance therapy in metastatic colorectal cancer: how long do we have to continue?

verfasst von: Dr. Jacopo Giuliani, MD, Marina Marzola

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Bevacizumab is a monoclonal antibody directed against vascular endothelial growth factor. Many phase III randomized clinical trials have showed the efficacy of bevacizumab in combination with cytotoxic chemotherapy for metastatic colorectal cancer (CRC), and the US Food and Drug Administration has approved its use in first-line or second-line schedules for metastatic CRC. However, no randomized studies are available to answer the questions about the role of bevacizumab as maintenance treatment after induction chemotherapy and how long to continue the maintenance treatment. We report an explicative case where both these topics are represented. This is a situation of possible feedback to daily clinical practice. Probably, only a multidisciplinary and shared treatment modality can help define the best treatment for patients in order to offer the best therapeutic strategy, where a standard approach is not defined.
Literatur
1.
Zurück zum Zitat Díaz-Rubio E, Gómez-España A, Massutí B, et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist. 2012;17(1):15–25.PubMedCrossRef Díaz-Rubio E, Gómez-España A, Massutí B, et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist. 2012;17(1):15–25.PubMedCrossRef
2.
Zurück zum Zitat Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42.PubMedCrossRef Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42.PubMedCrossRef
3.
Zurück zum Zitat Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12):1539–44.PubMedCrossRef Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12):1539–44.PubMedCrossRef
4.
Zurück zum Zitat Huh JW, Cho CK, Kim HR, et al. Impact of resection for primary colorectal cancer on outcomes in patients with synchronous colorectal liver metastases. J Gastrointest Surg. 2010;14(8):1258–64.PubMedCrossRef Huh JW, Cho CK, Kim HR, et al. Impact of resection for primary colorectal cancer on outcomes in patients with synchronous colorectal liver metastases. J Gastrointest Surg. 2010;14(8):1258–64.PubMedCrossRef
5.
Zurück zum Zitat Díaz-Rubio E, Pietrantonio F, de Braud F. Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colon rectal cancer. Oncologist. 2012;17(11):1426–8.PubMedCrossRef Díaz-Rubio E, Pietrantonio F, de Braud F. Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colon rectal cancer. Oncologist. 2012;17(11):1426–8.PubMedCrossRef
6.
Zurück zum Zitat Borofsky SE, Levine MS, Rubesin SE, Tanyi JL, Chu CS, Lev-Toaff AS. Bevacizumab-induced perforation of the gastrointestinal tract: clinical and radiographic findings in 11 patients. Abdom Imaging. 2012. doi:1007/s00261-012-9913-3. Borofsky SE, Levine MS, Rubesin SE, Tanyi JL, Chu CS, Lev-Toaff AS. Bevacizumab-induced perforation of the gastrointestinal tract: clinical and radiographic findings in 11 patients. Abdom Imaging. 2012. doi:1007/s00261-012-9913-3.
Metadaten
Titel
Single-agent bevacizumab as maintenance therapy in metastatic colorectal cancer: how long do we have to continue?
verfasst von
Dr. Jacopo Giuliani, MD
Marina Marzola
Publikationsdatum
01.06.2013
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-013-0071-2

Weitere Artikel der Ausgabe 2/2013

memo - Magazine of European Medical Oncology 2/2013 Zur Ausgabe